Price movement over the last 24 hours
Adaptive Biotechnologies Corp vs ZIM Integrated Shipping Services Ltd — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while ZIM Integrated Shipping Services Ltd trades at $24.63 (market cap $2.88B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and ZIM Integrated Shipping Services Ltd pays a 7.88% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ZIM | |
|---|---|---|
Market Cap | $3.33B | $2.88B |
Sector | Health | Industrials |
52-Week High | $22.37 | $29.27 |
52-Week Low | $10.24 | $12.44 |
Enterprise Value | $3.19B | $6.73B |
Dividend Yield | — | 7.88% |
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ZIM trades at $23.71, down 7.27% over 24 hours amid bearish technical signals and regulatory uncertainty around its proposed merger with Hapag-Lloyd. The company reported a Q1 2026 net loss of $86 million, missing EPS expectations, with revenue declining to $1.40 billion. Valuation metrics show a P/E of 28.91 and P/S of 0.45, while analyst sentiment is divided with a consensus price target of $16.75.
The outlook is clouded by merger risks and volatile freight rates, but the stock trades below book value, offering potential upside if the deal proceeds or asset value is realized. Key risks include regulatory hurdles and earnings volatility, requiring careful monitoring of merger developments and quarterly results.
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →